CF Therapeutics Development Network Coordinating Center: Clinical Trials

10 trials sponsored by CF Therapeutics Development Network Coordinating Center, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

9 completed, 1 terminated. 3 Phase 4, 2 Not applicable, 2 Phase 2, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 43Completed 3
Not applicable2Completed 2
Phase 22Completed 1, Terminated 1
Phase 11Completed 1

Follow CF Therapeutics Development Network Coordinating Center: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Testing the Effect of Adding Chronic Oral Azithromycin to Inhaled Tobramycin in People With Cystic Fibrosis (CF)
azithromycin, placebo (for azithromycin), inhaled tobramycin - Cystic Fibrosis
Phase 4CompletedSeattle Children's Hospital1192016-10-212021-06-28
Standardized Treatment of Pulmonary Exacerbations II
Standard of care IV antibiotic(s) - Pulmonary Cystic Fibrosis
Phase 4CompletedChris Goss9822016-06-012021-05-19
Early Methicillin-resistant Staphylococcus Aureus (MRSA) Therapy in Cystic Fibrosis (CF)
Rifampin, Trimethoprim/Sulfamethoxazole, Minocycline - Cystic Fibrosis, Methicillin-resistant Staphylococcus Aureus
Phase 2TerminatedUniversity of North Carolina, Chapel Hill472011-04-012017-05-15
Detection of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Activity in Rectal Tissues From Human Subjects
Cystic Fibrosis
CompletedCF Therapeutics Development Network Coordinating Center572009-10-012013-03-07
Infant Study of Inhaled Saline in Cystic Fibrosis
7% Hypertonic Saline (HS), 0.9% Isotonic Saline (IS) - Cystic Fibrosis
Not applicableCompletedCF Therapeutics Development Network Coordinating Center3212009-04-012013-02-12
Tolerability of Inhaled Hypertonic Saline in Infants With Cystic Fibrosis
inhaled 7% hypertonic saline (HS) - Cystic Fibrosis
Not applicableCompletedCF Therapeutics Development Network Coordinating Center192007-09-012011-08-24
Effect of Azithromycin on Lung Function in 6-18 Year-olds With Cystic Fibrosis (CF) Not Infected With P. Aeruginosa
azithromycin 250 mg tablets, placebo tablets - Cystic Fibrosis
Phase 4CompletedCF Therapeutics Development Network Coordinating Center2632007-02-012015-08-19
Safety Study of Orally Administered Curcuminoids in Adult Subjects With Cystic Fibrosis
standardized turmeric root extract - Cystic Fibrosis
Phase 1CompletedRamsey, Bonnie, MD112005-04-012007-12-25
The EPIC Observational Study
Cystic Fibrosis
CompletedCF Therapeutics Development Network Coordinating Center12482004-10-012019-02-01
Comparison of Two Treatment Regimens to Reduce PA Infection in Children With Cystic Fibrosis
Tobramycin solution for inhalation (TOBI), Oral placebo, Oral ciprofloxacin - Cystic Fibrosis, Pulmonary Disease, Chronic Obstructive
Phase 2CompletedSeattle Children's Hospital3042004-09-012014-02-28

Conditions studied

Cystic Fibrosis (10)  ·  Infections (1)  ·  Lung Diseases (1)  ·  Pseudomonas Infections (1)  ·  Pulmonary Disease, Chronic Obstructive (1)

Interventions

Azithromycin (2)  ·  Inhalation (2)  ·  Saline Solution, Hypertonic (2)  ·  Ciprofloxacin (1)  ·  Minocycline (1)  ·  Mupirocin (1)  ·  Rifampin (1)  ·  Saline Solution (1)  ·  Sodium Chloride (1)  ·  Tobramycin (1)  ·  Trimethoprim, Sulfamethoxazole Drug Combination (1)

Countries

United States (10)  ·  Canada (4)

Top investigators

Margaret Rosenfeld, MD, MPH (3)  ·  Chris Goss, MD (2)  ·  Felix Ratjen, MD, PhD (2)  ·  Stephanie Davis, MD (2)  ·  Bonnie W. Ramsey (1)  ·  Chris Goss, MD, MSc (1)  ·  David P Nichols, MD (1)  ·  Felix Ratjen, MD (1)  ·  George Retsch-Bogart, MD (1)  ·  JP Clancy, MD (1)  ·  Larry Lands, MD (1)  ·  Lisa Saiman, MD, MPH (1)  ·  Marianne S Muhlebach, MD (1)  ·  Michael Anstead, MD (1)  ·  Miriam Treggiari, MD (1)

Results publications

PMID 19470318, PMID 20442386, PMID 20597081, PMID 21893650, PMID 22554417, PMID 22595153, PMID 22610452, PMID 23742699, PMID 25972024, PMID 26288390, PMID 27852955, PMID 34159577, PMID 34469706, PMID 34933824, PMID 35300932, PMID 36511181, PMID 37963297, PMID 38096105

NIH funding

R01HL124053 (1), U01HL080310 (1), U01HL092931 (1), U01HL092932 (1)